CBER Director Peter Marks believes regulatory policies can help overcome barriers that are slowing gene therapy
Regulation
Emerging Company Profile
First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD
Data Byte
Opdivo started stronger, but has long since plateaued. Their sales differential
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
Discovery & Translation
BioCentury’s roundup of translational innovations
Finance
Plus: Centessa raises $100M in first follow-on since 2021 IPO
BioCentury ISSN 1097-7201